Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 for prevention of AVG thrombosis in ESRD
NCT05027074Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of MK-2060 in Arteriovenous graft thrombosis, sponsored by Merck & Co.. Started Sep 2021; status: completed.
02
Drugs
MK-2060
03
Conditions
Arteriovenous graft thrombosis
Beyond the preview
Go deeper on NCT05027074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027074.